Esperion Therapeutics, Inc. (NASDAQ:ESPR – Get Rating) CEO Sheldon L. Koenig sold 3,394 shares of the business’s stock in a transaction dated Monday, September 19th. The stock was sold at an average price of $6.94, for a total transaction of $23,554.36. Following the transaction, the chief executive officer now owns 198,257 shares in the company, valued at $1,375,903.58. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.
Esperion Therapeutics Price Performance
Esperion Therapeutics stock opened at $6.96 on Friday. The stock’s fifty day moving average price is $6.93 and its two-hundred day moving average price is $6.07. The firm has a market cap of $463.20 million, a PE ratio of -1.09 and a beta of 0.17. Esperion Therapeutics, Inc. has a one year low of $3.28 and a one year high of $13.14.
Esperion Therapeutics (NASDAQ:ESPR – Get Rating) last posted its quarterly earnings results on Tuesday, August 2nd. The biopharmaceutical company reported ($1.05) EPS for the quarter, missing analysts’ consensus estimates of ($0.95) by ($0.10). The company had revenue of $18.80 million during the quarter, compared to analyst estimates of $18.62 million. The firm’s quarterly revenue was down 53.8% compared to the same quarter last year. During the same period in the previous year, the business posted ($1.67) earnings per share. Sell-side analysts expect that Esperion Therapeutics, Inc. will post -3.81 earnings per share for the current fiscal year.
Institutional Trading of Esperion Therapeutics
Analyst Upgrades and Downgrades
ESPR has been the topic of several research analyst reports. Cowen dropped their price objective on Esperion Therapeutics to $13.00 in a research note on Tuesday, August 9th. Morgan Stanley boosted their price objective on Esperion Therapeutics from $5.00 to $7.00 and gave the stock an “underweight” rating in a report on Friday, July 15th. Finally, Credit Suisse Group lowered Esperion Therapeutics from a “neutral” rating to an “underperform” rating and lowered their target price for the stock from $7.00 to $6.00 in a research note on Wednesday, August 3rd. Three analysts have rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $12.63.
About Esperion Therapeutics
Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia.
- Get a free copy of the StockNews.com research report on Esperion Therapeutics (ESPR)
- The Institutions Hold On To Darden Restaurants International
- What Steelcase’s Earnings Say About the Return to the Office?
- Is The Golden Age Of Homebuilding Already Over?
- These 3 Big Dividend Payers Also Boast Strong Price Growth
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.